Stealth BioTherapeutics is a company developing drugs for treating mitochondrial disorders. The company was previously known as Stealth Peptides
Doctors believe that mitochondrial disorders cause damage to cells because they lead to faulty proteins inside mitochondria. The faulty proteins don’t “channel” energy efficiently and so they create more ROS than usual.
Mitochondria are damaged by too many ROS “floating around”, and the damaged mitochondria make the problem worse. The whole cell starts to be damaged. This is called “oxidative Stress”. The cell is struggling to get enough energy, its signalling mechanisms are damaged and it can’t do its job properly. The cell might go dormant or even die.
Bendavia and Ocuvia
Bendavia (also known as MTP-131) is a drug intended to protect mitochondria from damaging Reactive Oxygen Species (ROS). These are dangerous by-products of the processes inside mitochondria releasing energy from food and creating ATP, the “fuel” of the cell.
Ocuvia is a topical solution of MTP-131 applied to the eye rather than being injuected.
Bendavia and Ocuvia have been tested in the laboratory. It seems to improve the performance of cells with a mitochondrial disorder, and does not have any known harmful effects on healthy mitochondria.
Stealth BioTherapeutics is working with doctors to run clinical trials of Bendavia for several mitochondrial disorders.
- Leber Hereditary Optic Neuropathy (Ocuvia)
- Heart Failure
- Kidney Failure
- Mitochondrial Myopathy
- Mitochondrial Skeletal Muscle Dysfunction
- Diabetic Macular Edema
- Age-Related Macular Degeneration
For details of Stealth BioTherapeutics clinical trials Search the US Government Clinical Trials register for Stealth
The page was last updated August 15 2015